408 related articles for article (PubMed ID: 27896485)
1. Biomarkers for precision medicine in bladder cancer.
Kojima T; Kawai K; Miyazaki J; Nishiyama H
Int J Clin Oncol; 2017 Apr; 22(2):207-213. PubMed ID: 27896485
[TBL] [Abstract][Full Text] [Related]
2. Hope and challenge: Precision medicine in bladder cancer.
Su H; Jiang H; Tao T; Kang X; Zhang X; Kang D; Li S; Li C; Wang H; Yang Z; Zhang J; Li C
Cancer Med; 2019 Apr; 8(4):1806-1816. PubMed ID: 30907072
[TBL] [Abstract][Full Text] [Related]
3. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
4. Identification of an immunotherapy-responsive molecular subtype of bladder cancer.
Song BN; Kim SK; Mun JY; Choi YD; Leem SH; Chu IS
EBioMedicine; 2019 Dec; 50():238-245. PubMed ID: 31735557
[TBL] [Abstract][Full Text] [Related]
5. Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer.
Fang Z; Dai W; Wang X; Chen W; Shen C; Ye G; Li L
Tumour Biol; 2016 Jun; 37(6):8075-82. PubMed ID: 26715266
[TBL] [Abstract][Full Text] [Related]
6. microRNA expression profiles as decision-making biomarkers in the management of bladder cancer.
Amir S; Mabjeesh NJ
Histol Histopathol; 2017 Feb; 32(2):107-119. PubMed ID: 27586262
[TBL] [Abstract][Full Text] [Related]
7. Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer.
D'Andrea D; Hassler MR; Abufaraj M; Soria F; Ertl IE; Ilijazi D; Mari A; Foerster B; Egger G; Shariat SF
Expert Rev Anticancer Ther; 2018 Jul; 18(7):695-703. PubMed ID: 29737231
[TBL] [Abstract][Full Text] [Related]
8. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
[TBL] [Abstract][Full Text] [Related]
9. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
[TBL] [Abstract][Full Text] [Related]
10. Bladder cancer biomarkers: review and update.
Ghafouri-Fard S; Nekoohesh L; Motevaseli E
Asian Pac J Cancer Prev; 2014; 15(6):2395-403. PubMed ID: 24761840
[TBL] [Abstract][Full Text] [Related]
11. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
12. Unmasking molecular profiles of bladder cancer.
Piao XM; Byun YJ; Kim WJ; Kim J
Investig Clin Urol; 2018 Mar; 59(2):72-82. PubMed ID: 29520382
[TBL] [Abstract][Full Text] [Related]
13. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer.
Jiang X; Du L; Wang L; Li J; Liu Y; Zheng G; Qu A; Zhang X; Pan H; Yang Y; Wang C
Int J Cancer; 2015 Feb; 136(4):854-62. PubMed ID: 24961907
[TBL] [Abstract][Full Text] [Related]
14. Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer.
Fan J; Chen B; Luo Q; Li J; Huang Y; Zhu M; Chen Z; Li J; Wang J; Liu L; Wei Q; Cao D
Biomed Pharmacother; 2024 Apr; 173():116312. PubMed ID: 38417288
[TBL] [Abstract][Full Text] [Related]
15. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
16. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
17. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer.
Ruan W; Chen X; Huang M; Wang H; Chen J; Liang Z; Zhang J; Yu Y; Chen S; Xu S; Hu T; Li X; Guo Y; Jiang Z; Chen Z; Huang J; Lin T; Fan JB
Clin Epigenetics; 2021 Apr; 13(1):91. PubMed ID: 33902700
[TBL] [Abstract][Full Text] [Related]
18. mRNA, microRNA and lncRNA as novel bladder tumor markers.
Wieczorek E; Reszka E
Clin Chim Acta; 2018 Feb; 477():141-153. PubMed ID: 29224950
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
Dyrskjøt L; Reinert T; Algaba F; Christensen E; Nieboer D; Hermann GG; Mogensen K; Beukers W; Marquez M; Segersten U; Høyer S; Ulhøi BP; Hartmann A; Stöhr R; Wach S; Nawroth R; Schwamborn K; Tulic C; Simic T; Junker K; Harving N; Petersen AC; Jensen JB; Keck B; Grimm MO; Horstmann M; Maurer T; Steyerberg EW; Zwarthoff EC; Real FX; Malats N; Malmström PU; Ørntoft TF
Eur Urol; 2017 Sep; 72(3):461-469. PubMed ID: 28583312
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
